Read the full stored bill text
Req. No. 3505 Page 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
STATE OF OKLAHOMA
2nd Session of the 60th Legislature (2026)
SENATE BILL 2024 By: Deevers
AS INTRODUCED
An Act relating to pharmaceutical products; defining
terms; requiring manufacturers of pharmaceutical
products to publish certain list of ingredients;
specifying certain inclusions; clarifying
applicability; requiring certain submission and
publication; providing administrative, civil, and
criminal penalties and remedies; granting certain
protection; requiring establishment of certain
reporting system; preempting certain rulemaking;
providing certain construction; providing for
codification; and providing an effective date.
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 9002.1 of Title 63, unless there
is created a duplication in numbering, reads as follows:
As used in this act:
1. “Ingredient” includes:
a. all active and inactive components,
b. biological materials, such as mRNA, DNA from human or
animal sources, and viral vectors,
Req. No. 3505 Page 2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
c. synthetic materials, including lipids, nanotechnology
components, and polymers, and
d. adjuvants, preservatives, stabilizers, and other
additives;
2. “Manufacturer” means any person or entity engaged in the
production, preparation, propagation, compounding, or processing of
pharmaceutical products, as defined in Section 353.1 of Title 59 of
the Oklahoma Statutes; and
3. “Pharmaceutical product” means any drug or device as defined
in Section 353.1 of Title 59 of the Oklahoma Statutes including
prescription drugs, over-the-counter medications, vaccines, and
products intended for research purposes.
SECTION 2. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 9002.2 of Title 63, unless there
is created a duplication in numbering, reads as follows:
A. Manufacturers of pharmaceutical products, including those
intended exclusively for research purposes, shall publish a complete
and detailed list of all ingredients for each product.
1. The list shall include:
a. the chemical and common names of all active, inactive,
biological, and synthetic ingredients,
b. the origin of any biological materials, specifying
whether they are derived from human, animal, or
synthetic sources,
Req. No. 3505 Page 3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
c. the purpose of each ingredient, and
d. the quantity or concentration of each ingredient,
including trace elements and residuals.
2. For products containing mRNA or other gene-based technology,
the disclosure shall specify:
a. the sequence and source of any nucleic acids, and
b. the delivery mechanism, including synthetic carriers
such as lipid nanoparticles.
B. The ingredient information shall be:
1. Submitted to the State Board of Pharmacy;
2. Published publicly on a manufacturer-maintained website; and
3. Included in product labeling and marketing materials.
C. The responsibility to disclose all ingredients or components
of any pharmaceutical product, medical treatment, or mandate shall
remain unchanged regardless of whether a national emergency is
declared by the President of the United States or Congress. The
rights of individuals shall not be suspended, abridged, or infringed
during any declared emergency.
SECTION 3. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 9002.3 of Title 63, unless there
is created a duplication in numbering, reads as follows:
A. Noncompliance with the provisions of this act shall result
in the following penalties:
Req. No. 3505 Page 4
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1. Fines up to Fifty Thousand Dollars ($50,000.00) per
violation, per product; and
2. Suspension or revocation of the right to distribute or sell
the noncompliant pharmaceutical product within this state until
compliance is achieved.
B. Enhanced penalties for repeated or willful violations shall
be assessed as follows:
1. Escalating fines:
a. on a second violation: fines up to One Hundred
Thousand Dollars ($100,000.00) per product, and
b. on a third or subsequent violation: fines up to Two
Hundred Fifty Thousand Dollars ($250,000.00) per
product;
2. Prohibition of operations: For continued noncompliance, the
manufacturer may be prohibited from distributing or selling any
pharmaceutical products in this state for up to one (1) year; and
3. Criminal liability: Repeated or intentional
misrepresentation or omission of ingredient information is a
misdemeanor crime punishable by up to one (1) year of imprisonment.
C. The following civil remedies shall be available:
1. Private right to civil action: Any individual or group
harmed by noncompliance with this act, including misrepresentation
or omission of ingredient information, may bring a civil lawsuit
against the manufacturer for damages including, but not limited to:
Req. No. 3505 Page 5
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. economic damages including, but not limited to,
medical expenses or financial losses,
b. noneconomic damages including, but not limited to,
pain and suffering or emotional distress, and
c. punitive damages, as appropriate under Oklahoma law;
and
2. Class action suit: Affected individuals may form a class to
seek collective remedy in cases of widespread harm resulting from
noncompliance.
D. The State of Oklahoma may seek injunctive relief to compel
compliance or halt the distribution and sale of noncompliant
pharmaceutical products.
E. Individuals who report violations of this act by
manufacturers shall be protected from retaliation under applicable
whistleblower statutes and may be entitled to a percentage of fines
collected as a result of their report.
F. The State Board of Pharmacy shall establish a reporting
system for individuals to file complaints regarding suspected
violations of this act, with such reports forwarded to the
Legislature for review and potential enforcement action.
SECTION 4. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 9002.4 of Title 63, unless there
is created a duplication in numbering, reads as follows:
Req. No. 3505 Page 6
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
The Legislature shall retain exclusive rulemaking authority to
implement and enforce the provisions of this act.
SECTION 5. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 9002.5 of Title 63, unless there
is created a duplication in numbering, reads as follows:
To the extent any laws conflict with this act, this act shall
govern.
SECTION 6. This act shall become effective January 1, 2027.
60-2-3505 BRC 1/15/2026 10:26:03 AM